Medicine against parasites like Tapeworms and Giardia, contains a substance that kills Prostate- and colon cancer.
Cancer researchers at the University of Bergen (UiB) have in the recent years experienced with hundreds of known drugs, to see how they influence cancer cells.
Recently they found that a substance in medicine against parasites like Giardia and Tapeworms, acts like tailored medicine against prostate- and colon cancer.
“We discovered that this specific substance is blocking the signalling pathway in the cancer cells, and make them stop growing. It is not often that researchers discover a substance that targets specific molecules as precisely as this one, ” says Professor Karl-Henning Kalland at the Department of Clinical Science, at UiB. He is the leader of the Kalland´s Research Group.
The study is published in Nature Chemical Biology.
The researchers Yi Qu and Xisong Ke at Kalland team saw that the cells in prostate- and colon cancer contain high amounts of activated Beta-catenin. Activation of this protein makes the cells go amok and divides at high tempo. In addition, Beta-catenin makes the cancer cells more resistant and more able for survival.
In the study, Qu and Ke discovered that it was the substance NTZ (nitazoxanide), a well known and approved anti-parasite drug, that decompose the activated Beta-catenin.
“We are the first researchers who have mapped the complex molecular mechanisms involved in this process,” Kalland says.
Recycling old medicines
Experiments with well-known drugs show that a medicine may have different and unknown targets in the cells.
“The advantage of testing already approved drugs, is that we know they work in the human body and have no serious side effects, which means that a future treatment may happen quicker,” Kalland explains.
Strengthen the immune system
NTZ attacks cancer celles by hindering the activated Beta-catenin. It appears that this hindering also stimulates central parts of the immune system, that attacks cancer cells.
“At the moment, we are working on how to strengthen our on going immune therapy against prostate cancer by using the mechanisms we discovered of the NTZ,” Kalland says.
Kalland and his research-team is in the first phase in a clinical trial using immune therapy against prostate cancer.
Learn more: Tapeworm drug fights Prostate Cancer
The Latest on: Immune therapy
- Malaria research advances immunotherapy in lupus, HIVon November 19, 2019 at 3:03 pm
A new study published on November 19, 2019, in the journal Cell Reports, shows how the body’s immune system responds to malaria, which in turn promises to teach scientists how to design more effective ...
- Brain cancer immunotherapy developed at Roswell Park set for clinical trials next yearon November 19, 2019 at 2:38 pm
A drug called SurVaxM that is designed to treat a form of cancer called glioblastoma, will be used in a large clinical trial in 2020.
- Dr. Chaft on Investigational Neoadjuvant Immunotherapy Approaches in NSCLCon November 19, 2019 at 4:14 am
Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses investigational neoadjuvant immunotherapy approaches in non–small cell lung cancer (NSCLC). Investigators at ...
- Why Hasn’t Immunotherapy Been Working For Prostate Cancer? Bone Tumors May Be The Answeron November 18, 2019 at 4:00 pm
Researchers from MD Anderson in Texas have uncovered new clues as to why immunotherapy may fail in ... [+] many men with prostate cancer. Immunotherapy drugs called immune checkpoint inhibitors have ...
- Trispecific antibodies offer a third way forward for anticancer immunotherapyon November 18, 2019 at 8:11 am
Immunotherapy approaches seek to boost immune responses against cancer. A single antibody engineered to recognize three targets shows promise, when tested in animals, in improving the ability of T ...
- Immunotherapy Drugs Market : Key Facts and Forecast Predictions Presented Until 2025on November 17, 2019 at 10:21 pm
Nov 18, 2019 (AmericaNewsHour) -- Global Immunotherapy Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025 [104 pages report] This market research report includes a ...
- Findings could identify aggressive breast cancers that will respond to immunotherapyon November 14, 2019 at 9:29 am
The U.S. Food and Drug Administration recently approved a treatment that combines an immunotherapy drug and chemotherapy for triple negative breast cancer, but not all cases of this aggressive form of ...
- Cancer Immunotherapy Market Global Outlook by Size, Share, Trend, Growth, Demand, Industry Analysis, Business Strategies by 2023on November 13, 2019 at 4:25 pm
Amgen Inc., Bristol-Myers Squibb, ELI Lilly and Company, Celgene Corporation, Seattle Genetics, Inc., Spectrum Pharmaceuticals, Inc. Market Research Future has released a new research report on global ...
- Research explains why immunotherapy fails against prostate cancer bone metastaseson November 13, 2019 at 4:00 pm
The discoveries by a team led by Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at MD Anderson, explain why immunotherapy has been largely unsuccessful ...
- Rheumatoid Arthritis Is No Bar to Cancer Immunotherapyon November 13, 2019 at 1:17 pm
Among 22 RA patients treated with checkpoint inhibitors including ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda) -- 12 developed RA exacerbations after starting the ...
via Google News and Bing News